Glutathione Side Effects and Safety: What the Evidence Actually Shows

The most common glutathione side effects reported in short human studies of the oral form are mild and gut-related — occasional bloating, nausea, or cramping — but the safety picture changes substantially with injectable and intravenous (IV) glutathione, where the published literature documents endotoxin reactions, anaphylaxis, systemic inflammatory response, and severe skin reactions. Critically, no glutathione drug product is FDA-approved in the U.S. for any medical or cosmetic use; compounded injectable glutathione is an unapproved, prescription-only drug that the FDA has not evaluated for safety, quality, or efficacy (FDA). Below, we keep each route separate so the risks are not conflated.

What are the side effects of oral glutathione?

In short, controlled human trials, oral glutathione has been generally well tolerated. In a randomized, double-blind crossover study in 14 healthy adults (single 300–500 mg doses plus a 30-day safety follow-up), the only adverse events reported were 2 occurrences of moderate bloating and 3 of moderate nausea, and investigators detected no significant changes in liver function, kidney function, electrolytes, or complete blood count over 30 days (Antioxidants, 2026). Similarly, a 4-week oral “whitening” trial of 500 mg/day in 60 healthy adults found both glutathione and placebo were “very well tolerated,” though the authors noted long-term safety was not established (J Dermatolog Treat).

These trials were small and short. They do not establish long-term safety, and they say nothing about injectable use, which is a separate question entirely.

Does oral glutathione even reach the bloodstream?

One reason oral glutathione tends to be low-risk is also a reason its systemic effects are limited: it is poorly absorbed intact. In the gut, the enzyme gamma-glutamyltransferase cleaves the tripeptide into its constituent amino acids before it reaches the bloodstream, so even a single high oral dose of 3 g does not meaningfully raise systemic intact glutathione in human pharmacokinetic work (Buonocore et al., 2016). This bioavailability limitation is partly why some patients and clinics turn to injectable routes — which carry a very different and more serious risk profile. For a fuller discussion of the proposed roles of this molecule, see our overview of glutathione benefits.

Is IV or injectable glutathione dangerous?

Injectable and IV glutathione carry materially higher, better-documented risks than the oral form. The concerns fall into three buckets: contamination/endotoxin reactions, systemic inflammatory and allergic reactions, and severe skin reactions tied largely to unregulated cosmetic use.

Endotoxin contamination — two distinct, documented events. First, on February 1, 2019, the FDA warned compounders not to use a glutathione L-reduced powder distributed by Letco Medical to compound sterile injectable drugs, after 7 patients who received injectable glutathione experienced adverse events — nausea, vomiting, lightheadedness, chills, body aches, and sneezing within minutes, with one patient developing low blood pressure and difficulty breathing — attributed to potentially high endotoxin levels; the powder had been distributed to roughly 100 compounders in 30 states (Pharmacy Practice News; FDA). Separately, a peer-reviewed Australian investigation documented 7 cases of probable endotoxin poisoning from compounded IV glutathione infusions (5 of the 7 prescribed for “Lyme disease”): symptoms such as fever and rigors began within about 15 minutes to 2 hours, all samples exceeded the accepted pyrogenic threshold of 5 endotoxin units/kg/h, illness lasted roughly 3 days on average, and the index patient was hospitalized for 5 days (Epidemiol Infect, 2018). These are two separate clusters, not one event.

Systemic inflammatory response. A 2025 case report described a woman in her 30s who, within an hour of a high-dose IV glutathione “revitalizing” drip (Glutax 75GX DCRP), developed systemic inflammatory response syndrome with shock (systolic blood pressure 50–60 mmHg) and a temperature above 41°C, was admitted to the ICU, and recovered fully by 48 hours. Notably, she had been self-administering tirzepatide titrated to 7.5 mg weekly for weight loss (Cureus, 2025). The reaction was to the infusion; this is not a claim that tirzepatide caused it. We flag it because stacking unregulated IV drips is a real-world risk for people pursuing weight loss — a reason we steer patients toward supervised, evidence-based options such as those covered in our peptides for weight loss overview.

What about glutathione for skin lightening?

This is the highest-risk pattern in the literature, and it is also the one with the weakest efficacy evidence. The FDA Philippines Advisory No. 2019-182 warns against injectable glutathione for skin lightening, citing toxic effects on the liver, kidneys, and nervous system; the possibility of Stevens–Johnson syndrome; and the risk of transmitting HIV and hepatitis B and C when injections are non-sterile or given by non-medical practitioners. That advisory notes injectable glutathione is approved in the Philippines only as an adjunct in cisplatin chemotherapy — not for skin lightening — and that no published trials or dosing guidelines support cosmetic use (FDA Philippines).

The safety signal is concrete. A 2025 U.S. case report documented Stevens–Johnson syndrome in a 33-year-old woman after an IV infusion containing glutathione, vitamin C, and vitamin D at a wellness center (J Burn Care Res, 2025). And in a small placebo-controlled trial of IV glutathione 1200 mg twice weekly for 6 weeks for skin lightening, adverse effects were noted in all treated subjects: 8 of 16 women in the glutathione arm were excluded for deranged liver function tests and 1 for anaphylaxis, while only 6 of 16 (about 37.5%) showed improvement versus 3 of 16 on placebo (Zubair et al., JPAD). That is a small study (16 per arm), not a large RCT, and its results do not support skin-lightening efficacy.

How do glutathione side effects compare by route?

Route	Most-reported effects (by source)	Key context
Oral	Mild, dose-related GI effects: bloating, nausea, cramps (2 bloating, 3 nausea in n=14 crossover)	No significant LFT/renal/electrolyte/CBC changes over 30 days; poor systemic bioavailability (Antioxidants, 2026)
IV / injectable	Endotoxin reactions (fever, rigors, hypotension), anaphylaxis, SIRS, severe skin reactions	Two endotoxin clusters of 7 patients each; SIRS and SJS case reports; LFT derangement and 1 anaphylaxis in a 16-patient arm
Inhaled / nebulized	Bronchoconstriction in mild asthmatics (mean FEV1 fell 19%), cough, breathlessness	Sulfite-mediated; blocked by salbutamol (AJRCCM, 1997)

The inhaled effect is worth a separate note: nebulized glutathione induced clinically significant bronchoconstriction in patients with mild asthma — mean FEV1 fell 19% from baseline — an effect attributed to sulfite formation when glutathione is in solution and blocked by pretreatment with nebulized salbutamol (Am J Respir Crit Care Med, 1997). This is why people with asthma or sulfite sensitivity warrant particular caution.

Is supervised IV glutathione different from a “drip bar”?

Setting matters. In a randomized, double-blind Parkinson’s disease pilot (n=21; 11 glutathione, 10 placebo), IV glutathione 1400 mg three times weekly for 4 weeks was well tolerated, with no withdrawals due to adverse events and adverse events similar to placebo (Hauser et al., Mov Disord, 2009). That tells us controlled, clinically supervised IV use can be tolerated — but it is not a reassurance about unregulated “IV drip” settings, where the documented harms above (endotoxin, anaphylaxis, infection transmission) cluster. The difference between a pharmaceutical-grade, sterility-tested preparation given under medical supervision and a non-clinical drip is exactly the difference these reports highlight.

Who should avoid or use caution with glutathione?

Based on the signals above, the following groups warrant particular caution and a conversation with a licensed provider before any use:

• People with asthma or sulfite sensitivity — the bronchoconstriction signal applies specifically to inhaled/nebulized glutathione.
• People with liver disease — given the hepatotoxicity signal in the IV skin-lightening trial.
• Pregnant or breastfeeding individuals — there are no adequate human safety data, so use cannot be considered established as safe.
• Anyone considering non-clinical “IV glutathione drip” settings — because of contamination/endotoxin, anaphylaxis, and infection-transmission risk.

If you are weighing glutathione as part of a broader longevity or wellness plan, it is worth discussing alongside the rest of your regimen. You can learn more about evaluation through our how it works overview.

Frequently asked questions

Is glutathione FDA-approved?

No. There is no FDA-approved glutathione drug product in the United States for any medical or cosmetic indication. Compounded injectable glutathione is an unapproved, prescription-only drug, and the FDA has not evaluated it for safety, quality, or efficacy.

What are the most common side effects of oral glutathione?

In short, controlled human trials, the most common effects were mild and gut-related — occasional bloating, nausea, or cramping. One 14-person crossover study reported only 2 cases of moderate bloating and 3 of moderate nausea, with no significant changes in liver, kidney, electrolyte, or blood-count labs over 30 days. These trials were small and short and do not establish long-term safety.

Why is IV glutathione considered riskier than the oral form?

The published literature documents serious reactions with injectable/IV glutathione that have not been reported with the oral form, including endotoxin reactions (two separate clusters of 7 patients each), anaphylaxis, systemic inflammatory response syndrome, and Stevens–Johnson syndrome. Many of these reports involve unregulated or cosmetic injection settings.

Can glutathione cause an allergic or severe skin reaction?

Severe reactions have been reported. A 2025 U.S. case report documented Stevens–Johnson syndrome after an IV infusion containing glutathione and vitamins, and a small IV skin-lightening trial reported one case of anaphylaxis among 16 treated women. The FDA Philippines has also warned about Stevens–Johnson syndrome and organ toxicity with injectable use for skin lightening.

Does glutathione actually lighten skin?

The human efficacy evidence is weak. An oral whitening trial showed statistically significant melanin reduction versus placebo at only 2 of 6 measured sites, and a small IV trial showed improvement in roughly 37.5% of treated subjects with adverse effects in all of them. The FDA Philippines states no published trials support skin-lightening use. We make no skin-lightening claims.

Is glutathione safe during pregnancy or breastfeeding?

There are no adequate human safety data for glutathione during pregnancy or breastfeeding, so it cannot be considered established as safe. Anyone who is pregnant, breastfeeding, or planning pregnancy should speak with a licensed provider before using any form.